Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248


Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials.

Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S.

Eur Heart J. 2018 Dec 24. doi: 10.1093/eurheartj/ehy808. [Epub ahead of print]


Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR.

Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418.


A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease.

Mohammadi-Shemirani P, Sjaarda J, Gerstein HC, Treleaven DJ, Walsh M, Mann JF, McQueen MJ, Hess S, Paré G.

Clin Chem. 2019 Mar;65(3):427-436. doi: 10.1373/clinchem.2018.291104. Epub 2018 Oct 18.


Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators.

Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25.


Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.

Böhm M, Schumacher H, Teo KK, Lonn E, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder R, Weber M, Sliwa K, Williams B, Yusuf S.

Eur Heart J. 2018 Sep 1;39(33):3105-3114. doi: 10.1093/eurheartj/ehy287.


Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.


Advances in HIV-1 Vaccine Development.

Gao Y, McKay PF, Mann JFS.

Viruses. 2018 Apr 1;10(4). pii: E167. doi: 10.3390/v10040167. Review.


Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.

Gao Y, Wijewardhana C, Mann JFS.

Front Immunol. 2018 Feb 28;9:345. doi: 10.3389/fimmu.2018.00345. eCollection 2018. Review.


Blood HER2 and Uromodulin as Causal Mediators of CKD.

Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, Hess S, Paré G.

J Am Soc Nephrol. 2018 Apr;29(4):1326-1335. doi: 10.1681/ASN.2017070812. Epub 2018 Mar 6.


A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system.

Pankrac J, Klein K, McKay PF, King DFL, Bain K, Knapp J, Biru T, Wijewardhana CN, Pawa R, Canaday DH, Gao Y, Fidler S, Shattock RJ, Arts EJ, Mann JFS.

NPJ Vaccines. 2018 Jan 19;3:2. doi: 10.1038/s41541-017-0040-6. eCollection 2018.


Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Buse JB.

N Engl J Med. 2017 Nov 30;377(22):2197-2198. doi: 10.1056/NEJMc1713042. No abstract available.


Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J.

J Am Soc Nephrol. 2018 Jan;29(1):317-325. doi: 10.1681/ASN.2017060713. Epub 2017 Oct 17.


Eradication of HIV-1 latent reservoirs through therapeutic vaccination.

Pankrac J, Klein K, Mann JFS.

AIDS Res Ther. 2017 Sep 12;14(1):45. doi: 10.1186/s12981-017-0177-4. Review.


Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.


Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.

Papademetriou V, Nylen ES, Doumas M, Probstfield J, Mann JFE, Gilbert RE, Gerstein HC.

Am J Med. 2017 Dec;130(12):1465.e27-1465.e39. doi: 10.1016/j.amjmed.2017.05.047. Epub 2017 Aug 31.


Mortality in dialysis patients with cinacalcet use: A large observational registry study.

Friedl C, Reibnegger G, Kramar R, Zitt E, Pilz S, Mann JFE, Rosenkranz AR.

Eur J Intern Med. 2017 Jul;42:89-95. doi: 10.1016/j.ejim.2017.05.002. Epub 2017 May 10.


An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients.

Bagaya BS, Tian M, Nickel GC, Vega JF, Li Y, He P, Klein K, Mann JFS, Jiang W, Arts EJ, Gao Y.

J Mol Biol. 2017 Jul 7;429(14):2246-2264. doi: 10.1016/j.jmb.2017.04.016. Epub 2017 May 1.


Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.

Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S.

Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.


Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses.

McKay PF, Mann JF, Pattani A, Kett V, Aldon Y, King D, Malcolm RK, Shattock RJ.

J Control Release. 2017 Mar 10;249:74-83. doi: 10.1016/j.jconrel.2017.01.018. Epub 2017 Jan 21.


Dietary Sodium and Cardiovascular Disease Risk.

O'Donnell M, Mann JF, Schutte AE, Staessen JA, Lopez-Jaramillo P, Thomas M, Mente A, Saulnier PJ, Yusuf S.

N Engl J Med. 2016 Dec 15;375(24):2404-2406. doi: 10.1056/NEJMc1612304. No abstract available.


Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.

Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, Teo KK, Yusuf S, Mann JF.

Kidney Int. 2017 Mar;91(3):683-690. doi: 10.1016/j.kint.2016.09.038. Epub 2016 Dec 4.


First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.

Choi E, Michalski CJ, Choo SH, Kim GN, Banasikowska E, Lee S, Wu K, An HY, Mills A, Schneider S, Bredeek UF, Coulston DR, Ding S, Finzi A, Tian M, Klein K, Arts EJ, Mann JF, Gao Y, Kang CY.

Retrovirology. 2016 Nov 28;13(1):82.


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.


Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.

Mente A, O'Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R, Mony P, Yusuf R, Yusoff K, Szuba A, Oguz A, Rosengren A, Bahonar A, Yusufali A, Schutte AE, Chifamba J, Mann JF, Anand SS, Teo K, Yusuf S; PURE, EPIDREAM and ONTARGET/TRANSCEND Investigators.

Lancet. 2016 Jul 30;388(10043):465-75. doi: 10.1016/S0140-6736(16)30467-6. Epub 2016 May 20. Review.


Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.

Kim JW, Auffinger B, Spencer DA, Miska J, Chang AL, Kane JR, Young JS, Kanojia D, Qiao J, Mann JF, Zhang L, Wu M, Ahmed AU, Aboody KS, Strong TV, Hébert CD, Lesniak MS.

J Transl Med. 2016 May 16;14(1):134. doi: 10.1186/s12967-016-0895-8.


CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice.

Mann JF, Tregoning JS, Aldon Y, Shattock RJ, McKay PF.

J Control Release. 2016 Jun 28;232:75-82. doi: 10.1016/j.jconrel.2016.04.022. Epub 2016 Apr 16.


Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study.

Smyth A, Griffin M, Yusuf S, Mann JF, Reddan D, Canavan M, Newell J, O'Donnell M.

J Ren Nutr. 2016 Sep;26(5):288-98. doi: 10.1053/j.jrn.2016.01.016. Epub 2016 Mar 12.


Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.

Krane V, Schmidt KR, Gutjahr-Lengsfeld LJ, Mann JF, März W, Swoboda F, Wanner C; 4D Study Investigators (the German Diabetes and Dialysis Study Investigators).

Kidney Int. 2016 Jun;89(6):1380-7. doi: 10.1016/j.kint.2015.12.033. Epub 2016 Feb 17.


TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.

McKay PF, King DF, Mann JF, Barinaga G, Carter D, Shattock RJ.

PLoS One. 2016 Feb 10;11(2):e0148984. doi: 10.1371/journal.pone.0148984. eCollection 2016.


LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.

Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR; LEADER investigators.

J Hypertens. 2016 Jun;34(6):1140-50. doi: 10.1097/HJH.0000000000000890.


Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study.

Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R; ONTARGET Investigators.

Am J Kidney Dis. 2016 Jul;68(1):29-40. doi: 10.1053/j.ajkd.2015.12.019. Epub 2016 Jan 30.


Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators.

N Engl J Med. 2015 Dec 3;373(23):2225-36. doi: 10.1056/NEJMoa1415463.


Intraprocedural reduction of the veno-arterial norepinephrine gradient correlates with blood pressure response after renal denervation.

Tiroch K, Sause A, Szymanski J, Nover I, Leischik R, Mann JF, Vorpahl M, Seyfarth M.

EuroIntervention. 2015 Nov;11(7):824-34. doi: 10.4244/EIJV11I7A167.


Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice.

King DF, McKay PF, Mann JF, Jones CB, Shattock RJ.

PLoS One. 2015 Nov 6;10(11):e0141557. doi: 10.1371/journal.pone.0141557. eCollection 2015.


Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union.

Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv76-85. doi: 10.1093/ndt/gfv086.


Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes.

Regele F, Jelencsics K, Shiffman D, Paré G, McQueen MJ, Mann JF, Oberbauer R.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv26-34. doi: 10.1093/ndt/gfv087. Review.


Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?

Mann JF, Rossing P, Wiȩcek A, Rosivall L, Mark P, Mayer G.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv1-5. doi: 10.1093/ndt/gfv120. Review.


Risk Prediction for Early CKD in Type 2 Diabetes.

Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, Teo KK, Gerstein H, Mann JF, Oberbauer R; ONTARGET and ORIGIN Investigators.

Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1371-9. doi: 10.2215/CJN.10321014. Epub 2015 Jul 14.


Dual renin-angiotensin system blockade and outcome benefits in hypertension: a narrative review.

Mann JF, Böhm M.

Curr Opin Cardiol. 2015 Jul;30(4):373-7. doi: 10.1097/HCO.0000000000000173. Review.


Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study).

Gesualdo L, Combe C, Covic A, Dellanna F, Goldsmith D, London G, Mann JF, Zaoui P, Turner M, Muenzberg M, MacDonald K, Abraham I.

Int Urol Nephrol. 2015 May;47(5):837-45. doi: 10.1007/s11255-015-0970-8. Epub 2015 Apr 17.


Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.

Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM; Sucroferric Oxyhydroxide Study Group.

Nephrol Dial Transplant. 2015 Jun;30(6):1037-46. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16.


Multiglandular hormone deficiency in a patient with systemic capillary leak syndrome.

Then C, Ritzel K, Seibold C, Mann JF, Reincke M.

Case Rep Med. 2015;2015:958283. doi: 10.1155/2015/958283. Epub 2015 Jan 5.


LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Daniels GH, Hegedüs L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbøl J, Moses AC, Buse JB, Tuttle RM; LEADER Trial Investigators.

Diabetes Obes Metab. 2015 May;17(5):477-86. doi: 10.1111/dom.12444. Epub 2015 Feb 23.


Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL.

Schuh E, Ertl-Wagner B, Lohse P, Wolf W, Mann JF, Lee-Kirsch MA, Hohlfeld R, Kümpfel T.

Neurol Neuroimmunol Neuroinflamm. 2014 Dec 23;2(1):e55. doi: 10.1212/NXI.0000000000000055. eCollection 2015 Feb. No abstract available.


Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, Gao P, Gerstein H, Yusuf S, Oberbauer R, Mann JF; ONTARGET Investigators.

Kidney Int. 2015 Apr;87(4):784-91. doi: 10.1038/ki.2014.370. Epub 2014 Dec 10.


Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.

Böhm M, Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, Sleight P, Mancia G, Linz D, Mahfoud F, Ukena C, Sliwa K, Bakris G, Yusuf S.

J Intern Med. 2015 Jul;278(1):38-49. doi: 10.1111/joim.12333. Epub 2014 Dec 22.


LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators.

Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229.


A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND.

Shiffman D, Pare G, Oberbauer R, Louie JZ, Rowland CM, Devlin JJ, Mann JF, McQueen MJ.

PLoS One. 2014 Sep 19;9(9):e106631. doi: 10.1371/journal.pone.0106631. eCollection 2014.


The relationship between estimated sodium and potassium excretion and subsequent renal outcomes.

Smyth A, Dunkler D, Gao P, Teo KK, Yusuf S, O'Donnell MJ, Mann JF, Clase CM; ONTARGET and TRANSCEND investigators.

Kidney Int. 2014 Dec;86(6):1205-12. doi: 10.1038/ki.2014.214. Epub 2014 Jun 11.


Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.

ORIGIN trial investigators, Gilbert RE, Mann JF, Hanefeld M, Spinas G, Bosch J, Yusuf S, Gerstein HC.

Diabetologia. 2014 Jul;57(7):1325-31. doi: 10.1007/s00125-014-3238-4. Epub 2014 Apr 26.


Supplemental Content

Support Center